Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old
2014年8月31日 更新者：Ana Beatriz Winter Tavares、Universidade Federal do Rio de Janeiro
The growth hormone (GH) secretion declines gradually with age, with studies demonstrating a progressive reduction of 14% secretion per decade of life beginning in the second decade.
Other studies suggest a disruption in GH secretion in elderly people.
These findings suggest a possible association between growth hormone deficiency (GHD) and the ageing process.GH replacement is well known to improve body composition, leading to a decrease in total body fat and an increase in lean body mass.
However, GH replacement has only shown an effect on muscle strength in GH-deficient adults subjected to long-term GH therapy.
Few studies have evaluated the effect of GH replacement on muscle strength in elderly people engaged in a program of exercise training.Our purpose is to evaluate the effect of GH therapy on muscle strength in healthy, non-sedentary men over 50 years old.
研究概览
详细说明
At baseline, subjects are submitted to evaluation of GH secretion, testosterone level, body composition, and muscle strength.
Absence of GHD and normal testosterone levels were necessary for the inclusion in the study.
These parameters will be evaluated after 6 months of GH use x placebo.
研究类型
介入性
注册 (实际的)
13
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Rio de Janeiro、巴西、21941-913
- Hospital Universitário Clementino Fraga Filho - UFRJ
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
50年 至 70年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Healthy and non-sedentary men aged 50-70 years
Exclusion Criteria:
- pituitary disease, GH use in the last 12 months, severe acute disease, hepatic and/or renal chronic disease, uncontrolled systemic arterial hypertension, diabetes mellitus, psychiatric disorders, history of cancer, non-treated hypogonadism and the presence of any other disease that could interfere with the somatotrophic axis.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：预防
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：growth hormone
GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively.
The last GH dose will be maintained until the end of the study (6 months).
|
GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively.
The last GH dose will be maintained until the end of the study.
These GH dosages were based on the dose used for adults of the same age with GHD.
Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Muscle strength after GH replacement
大体时间：after 6 months of GH replacement
|
Muscle strength is evaluated for the maximum strength based on the concept of maximum repetition (1 MR) (i.e., the maximum load that can be performed using the correct technique for an exercise).The exercises evaluated were bench press and leg press.
To determine the load associated with 10 MR, each subject can initially performed 10 repetitions of each exercise with a sub maximum load, which is considered a load that was possible to mobilise.
Then, the loads are progressively increased and with a maximum of 3 trials, the load of 10 MR is reached.
During the 10 MR test, a 2-5 minute interval is provided between the attempts of each exercise.
After the load was obtained for a determined exercise, intervals not less than 10 minutes were given before moving on to the next exercise.
|
after 6 months of GH replacement
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
body composition after growth hormone replacement
大体时间：after 6 months of growth hormone
|
Body mass index is calculated using Quetelet's formula (weight/height2) and the percentage of body fat was calculated using the adipometer on seven cutaneous folds (tricipital, subscapular, suprailiac, pectoral, axillary, abdominal and thigh) according to the Pollock and Jackson protocol.
Abdominal circumference is measured using a non-elastic tape at the greatest diameter between the last ribs and the iliac crests.
The same person examined all subjects.
|
after 6 months of growth hormone
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Ana Beatriz tavares、Hospital Universitário Clementino Fraga Filho - UFRJ
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年1月1日
初级完成 (实际的)
2013年6月1日
研究完成 (实际的)
2013年6月1日
研究注册日期
首次提交
2013年5月7日
首先提交符合 QC 标准的
2013年5月10日
首次发布 (估计)
2013年5月15日
研究记录更新
最后更新发布 (估计)
2014年9月3日
上次提交的符合 QC 标准的更新
2014年8月31日
最后验证
2014年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.